Lonza’s Synaffix has secured two separate licensing deals with Boehringer Ingelheim and Japanese drugmaker Mitsubishi Tanabe Pharma for its antibody-drug conjugate tech.
The two “long-term” deals were announced Thursday. While details are sparse, including information ...
↧